These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24805288)

  • 21. Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.
    Vlaming ML; van Duijn E; Dillingh MR; Brands R; Windhorst AD; Hendrikse NH; Bosgra S; Burggraaf J; de Koning MC; Fidder A; Mocking JA; Sandman H; de Ligt RA; Fabriek BO; Pasman WJ; Seinen W; Alves T; Carrondo M; Peixoto C; Peeters PA; Vaes WH
    Clin Pharmacol Ther; 2015 Aug; 98(2):196-204. PubMed ID: 25869840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applications of accelerator MS in pediatric drug evaluation.
    Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
    Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A method for the quantitation of conjugated bile acids in dried blood spots using electrospray ionization-mass spectrometry.
    Mills KA; Mushtaq I; Johnson AW; Whitfield PD; Clayton PT
    Pediatr Res; 1998 Mar; 43(3):361-8. PubMed ID: 9505275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
    DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808.
    Kim A; Yu BY; Dueker SR; Shin KH; Kim HS; Ahn H; Cho JY; Yu KS; Jang IJ; Lee H
    Clin Pharmacol Ther; 2017 Sep; 102(3):537-546. PubMed ID: 28214288
    [No Abstract]   [Full Text] [Related]  

  • 27. Adding value through accelerator mass spectrometry-enabled first in human studies.
    Seymour MA
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):640-647. PubMed ID: 27444819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroscience and accelerator mass spectrometry.
    Palmblad M; Buchholz BA; Hillegonds DJ; Vogel JS
    J Mass Spectrom; 2005 Feb; 40(2):154-9. PubMed ID: 15706618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.
    Gao L; Li J; Kasserra C; Song Q; Arjomand A; Hesk D; Chowdhury SK
    Anal Chem; 2011 Jul; 83(14):5607-16. PubMed ID: 21627104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitating isotopic molecular labels with accelerator mass spectrometry.
    Vogel JS; Love AH
    Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overdose of ursodiol in preterm infant is well tolerated.
    Goodwin R; Hannum J; Clark R
    Pediatr Emerg Care; 2006 Aug; 22(8):619. PubMed ID: 16912636
    [No Abstract]   [Full Text] [Related]  

  • 32. Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.
    Jiang H; Zeng J; Li W; Bifano M; Gu H; Titsch C; Easter J; Burrell R; Kandoussi H; Aubry AF; Arnold ME
    Anal Chem; 2012 Nov; 84(22):10031-7. PubMed ID: 23106420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of early human data on clinical development: there is time to win.
    Swart P; Lozac'h F; Simon M; van Duijn E; Vaes WH
    Drug Discov Today; 2016 Jun; 21(6):873-9. PubMed ID: 27046542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
    Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Sadiq MW; Salehpour M; Forsgard N; Possnert G; Hammarlund-Udenaes M
    Drug Metab Dispos; 2011 Feb; 39(2):174-9. PubMed ID: 21059857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India.
    Sharma PK; Garg SK; Narang A
    Indian J Med Res; 2003 Apr; 117():164-9. PubMed ID: 14604305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology.
    White IN; Brown K
    Trends Pharmacol Sci; 2004 Aug; 25(8):442-7. PubMed ID: 15276714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.
    Combes B; Carithers RL; Maddrey WC; Lin D; McDonald MF; Wheeler DE; Eigenbrodt EH; Muñoz SJ; Rubin R; Garcia-Tsao G
    Hepatology; 1995 Sep; 22(3):759-66. PubMed ID: 7657280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
    Lappin G; Stevens L
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.